NZ599097A - Chimeric antibodies specific for cd151 and use thereof in the treatment of cancer - Google Patents

Chimeric antibodies specific for cd151 and use thereof in the treatment of cancer

Info

Publication number
NZ599097A
NZ599097A NZ599097A NZ59909710A NZ599097A NZ 599097 A NZ599097 A NZ 599097A NZ 599097 A NZ599097 A NZ 599097A NZ 59909710 A NZ59909710 A NZ 59909710A NZ 599097 A NZ599097 A NZ 599097A
Authority
NZ
New Zealand
Prior art keywords
cancer
treatment
antibodies specific
chimeric antibodies
binds
Prior art date
Application number
NZ599097A
Inventor
Jean-Francois Haeuw
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of NZ599097A publication Critical patent/NZ599097A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

599097 Disclosed is a chimeric antibody that binds to CD151 comprising a light chain and a heavy chain sequences DIVLSQSPASLALSLGQRATISCRASASVEYYGTSLMHWYQQKPGQPPKLLIYEASNVESGVPARFSGSGSGTDFSLNIHPVEEDDLAIYFCQQSRKAPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC and EVKLVESGGGLVQPGGSLKLSCAASGFTFSTYTMSWVRQTPEKRLEWVAYISSGGGTTYYPDTVKGRFTISRDNARNTLYLQMNSLKSEDTAMYYCATPRIGTGFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK, respectively.
NZ599097A 2009-10-09 2010-10-08 Chimeric antibodies specific for cd151 and use thereof in the treatment of cancer NZ599097A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09305964A EP2308897A1 (en) 2009-10-09 2009-10-09 Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer
US26602009P 2009-12-02 2009-12-02
PCT/EP2010/065085 WO2011042534A1 (en) 2009-10-09 2010-10-08 Chimeric antibodies specific for cd151 and use thereof in the treatment of cancer

Publications (1)

Publication Number Publication Date
NZ599097A true NZ599097A (en) 2014-03-28

Family

ID=41682879

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ599097A NZ599097A (en) 2009-10-09 2010-10-08 Chimeric antibodies specific for cd151 and use thereof in the treatment of cancer

Country Status (19)

Country Link
US (1) US20120275997A1 (en)
EP (2) EP2308897A1 (en)
JP (1) JP2013507114A (en)
KR (1) KR20120094474A (en)
CN (1) CN102597004A (en)
AR (1) AR078572A1 (en)
AU (1) AU2010305360A1 (en)
BR (1) BR112012008266A2 (en)
CA (1) CA2775634A1 (en)
IL (1) IL219034A0 (en)
IN (1) IN2012DN02696A (en)
MA (1) MA33668B1 (en)
MX (1) MX2012004059A (en)
NZ (1) NZ599097A (en)
RU (1) RU2012113418A (en)
TN (1) TN2012000151A1 (en)
TW (1) TW201118168A (en)
WO (1) WO2011042534A1 (en)
ZA (1) ZA201202291B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2013125221A1 (en) * 2012-02-21 2015-07-30 静岡県 Affinity ligand for antibody purification
JP6386995B2 (en) * 2013-04-08 2018-09-05 テオリアサイエンス株式会社 Colorectal cancer detection method

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (en) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd Humanized b-b10
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6245898B1 (en) * 1998-06-15 2001-06-12 The Research Foundation Of State University Of New York Monoclonal antibodies that recognize antigens associated with tumor metastasis
US8227576B2 (en) * 2006-03-30 2012-07-24 Glaxo Group Limited Antibodies against amyloid-β peptide
AU2007285217B2 (en) * 2006-08-14 2013-02-07 Forerunner Pharma Research Co., Ltd Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
GB0619291D0 (en) * 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
FR2907341B1 (en) * 2006-10-18 2012-08-17 Pf Medicament USE OF ANTI-CD151 ANTIBODY FOR THE TREATMENT OF CANCER
CN104650235A (en) * 2007-11-30 2015-05-27 葛兰素集团有限公司 Antigen-Binding Constructs
FR2929946B1 (en) * 2008-04-11 2010-05-28 Pf Medicament NOVEL ANTI-CD151 ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER

Also Published As

Publication number Publication date
RU2012113418A (en) 2013-11-20
CN102597004A (en) 2012-07-18
WO2011042534A1 (en) 2011-04-14
TN2012000151A1 (en) 2013-12-12
ZA201202291B (en) 2012-11-28
BR112012008266A2 (en) 2019-09-24
EP2486057A1 (en) 2012-08-15
KR20120094474A (en) 2012-08-24
CA2775634A1 (en) 2011-04-14
MX2012004059A (en) 2012-05-22
MA33668B1 (en) 2012-10-01
US20120275997A1 (en) 2012-11-01
JP2013507114A (en) 2013-03-04
EP2308897A1 (en) 2011-04-13
IN2012DN02696A (en) 2015-09-04
TW201118168A (en) 2011-06-01
AR078572A1 (en) 2011-11-16
AU2010305360A1 (en) 2012-04-19
IL219034A0 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
NZ616382A (en) Antibodies specific to cadherin-17
NZ592215A (en) c-MET ANTIBODIES
NZ712765A (en) Antibodies that bind csf1r
NZ600262A (en) Anti-her3 antibodies and uses thereof
NZ700437A (en) Anti-cmet antibody and its use for the detection and the diagnosis of cancer
GB2488091A (en) Humanized anti-interleukin 3 receptor alpha chain antibodies
NZ702680A (en) Anti-gd2 antibodies
NZ597664A (en) Humanized anti-cdcp1 antibodies
NZ584658A (en) Antibodies that bind il-4 and/or il-13 and their uses
MX2010002406A (en) Combination therapy with type i and type ii anti-cd20 antibodies.
MX341958B (en) Antibodies against human il33r and uses thereof.
MX2019014658A (en) Humanized antibodies that recognize alpha-synuclein.
NZ594339A (en) Anti-fgfr3 antibodies and methods using same
WO2013173496A3 (en) Cd33 antibodies and use of same to treat cancer
NZ600022A (en) Anti CD37 antibodies
NZ601584A (en) Methods for treating colorectal cancer
NZ610976A (en) Anti-mesothelin antibodies and immunoconjugates
MY159553A (en) Detection and treatment of pancreatic, ovarian and other cancers
NZ586053A (en) Anti-vegf antibody compositions and methods
NZ724971A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
NZ611785A (en) Anti-notch1 antibodies
NZ599140A (en) Antibodies that specifically bind to the epha2 receptor
NZ603607A (en) Cgrp antibodies
TR201815254T4 (en) ANTIBODIES CONNECTED TO TL1A AND THEIR USES
NZ618067A (en) Anti-cd100 antibodies and methods for using the same

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 OCT 2015 BY ACUMASS

Effective date: 20140923

LAPS Patent lapsed